source
- Bayer agrees to acquire ophthalmology biotech Perfuse Therapeutics for $300 million upfrontBayer announced it will purchase Perfuse Therapeutics, a company focused on eye-disease treatments, for an upfront payment of $300 million. The acquisition includes Perfuse's mid-stage program that…
- Amgen and AbbVie report Inflation Reduction Act negotiations dent Q1 salesAmgen and AbbVie disclosed in their first-quarter earnings that the Inflation Reduction Act is already affecting their sales. The companies said the first set of drug-price negotiations required b…